The 2022–23 Patient Experience Survey data shows that many Australians struggle to afford the medicines they need and that cost barriers to access have increased compared with the previous year.

This report describes trends in the use of prescription medicines covered by the Pharmaceutical Benefits Scheme and the Repatriation Pharmaceutical Benefits Scheme. It provides data on the usage rates of – and Australian Government spending on – prescription medicines.

The purpose of this Inquiry is to investigate the legislative and regulatory framework for workplace drug testing, including the treatment of prescription medicinal cannabis compared to other prescription medications. The Committee aimed to understand whether the framework can be improved and whether current workplace drug testing laws and procedures are discriminatory.

AURA 2023 reports on patterns and trends in antimicrobial use and appropriateness and antimicrobial resistance in Australian acute and community healthcare settings. The report highlights trends and areas of concern and suggests priorities for action.

This study was aimed at understanding the attitudes and positions of key Australian organisational and political stakeholders towards using psychedelic agents in medically supervised environments to treat mental health conditions.